Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D

Kowalski, Jacek; Adkins, Karissa; Gangolli, Seema; Ren, Junling; Arendt, Heather; DeStefano, Joanne; Obregon, Jennifer; Tummolo, Donna; Natuk, Robert J.; Brown, Tom; Parks, Christopher L.; Udem, Stephen A.; Long, Debra L.

doi:10.1016/j.vaccine.2006.11.063

Cited by 10 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although safety issues of alphaviruses as a vaccine vector are not addressed in this paper, it is also critical for clinical application of the platform. It has been stated that no pathogenic effect was observed upon replicon particle immunization (25). In the present study, we noticed early deaths after challenge in the group immunized with 10 3 IU ( Fig.…”

Section: Figmentioning

confidence: 99%

Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity

Uematsu

Vajdy

Lian

et al. 2012

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

bAntivector immunity has been recognized as a potential caveat of using virus-based vaccines. In the present study, an alphavirusbased replicon particle vaccine platform, which has demonstrated robust immunogenicity in animal models, was tested for effects of antivector immunity on immunogenicity against hemagglutinin of influenza virus as a target antigen and efficacy for protection against lethal challenge with the virus. Chimeric alphavirus-based replicon particles, comprising Venezuelan equine encephalitis virus nonstructural and Sindbis virus structural components, induced efficient protective antibody responses, which were not adversely influenced after multiple immunizations with the same vector expressing various antigens.

show abstract

Section: Figmentioning

confidence: 99%

Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity

Uematsu

Vajdy

Lian

et al. 2012

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…The high level of gene expression from single-cycle alphavirus RNA replicon vectors that specifically target to dendritic cells [27] may induce better immune responses than other vaccine delivery systems. In addition, alphavirus replicon vaccines contain a single-cycle, replication-incompetent RNA vector that has no DNA intermediate form and amplifies RNA only in the cytoplasm, which may offer a significant safety advantage over DNA vaccines where the vaccine construct can be detected up to one year post-vaccination, increasing the risk of integration into the host genome [28].…”

Section: Discussionmentioning

confidence: 99%

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

Reap

Morris

Dryga

et al. 2007

Vaccine

View full text Add to dashboard Cite

We used a replication-incompetent, single-cycle, alphavirus replicon vector system to produce viruslike replicon particles (VRP) expressing the extracellular domain of human cytomegalovirus (CMV) glycoprotein B or a pp65/IE1 fusion protein. Efficient production methods were scaled to produce pilot lots and clinical lots of each alphavirus replicon vaccine component. The vaccine induced hightitered antibody responses in mice and rabbits, as measured by ELISA and CMV neutralization assays, and robust T-cell responses in mice, as measured by IFN-γ ELISPOT assay. A toxicity study in rabbits showed no adverse effects in any toxicology parameter. These studies support clinical testing of this novel CMV alphavirus replicon vaccine in humans.

show abstract

“…Other studies have used the mouse model of intracranial (IC) injection to demonstrate the safety of RP. IC injection of VEEV RP resulted in only transient pathology (1–2 days) and weight loss (1 day) with a rapid return to pre-injection status (Kowalski et al , 2007). The neurovirulence of both SIN and SFV RP expressing LacZ has also been evaluated following IC inoculation.…”

Section: Safetymentioning

confidence: 99%

Alphavirus replicon vaccines

Veen

Harris

Kamrud

2012

Anim. Health. Res. Rev.

View full text Add to dashboard Cite

AbstractThe alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.

show abstract

Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D

Cited by 10 publications

References 42 publications

Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity

Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

Alphavirus replicon vaccines

Contact Info

Product

Resources

About